Controversies in the Treatment of Wet Age-related Macular Degeneration
[...]Genentech has modified the molecule of bevacizumab without affecting the basis of its efficacy and now specifically addressed to treating this pathology. [...]ranibizumab was developed, it is forty times more expensive, although no indirect comparisons have proved significant differences betwee...
Gespeichert in:
| Veröffentlicht in: | American journal of ophthalmology 2008-05, Vol.145 (5), p.937-937 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 937 |
|---|---|
| container_issue | 5 |
| container_start_page | 937 |
| container_title | American journal of ophthalmology |
| container_volume | 145 |
| creator | Flores Moreno, Sandra Bautista Paloma, Javier |
| description | [...]Genentech has modified the molecule of bevacizumab without affecting the basis of its efficacy and now specifically addressed to treating this pathology. [...]ranibizumab was developed, it is forty times more expensive, although no indirect comparisons have proved significant differences between both treatments in efficacy.1-2 In this case, countries such as Italy, Germany, Austria, Finland, and New Zealand, is formally recommended to use bevacizumab instead of ranibizumab in AMD, while waiting for a head-to-head trial, which had to be promoted by independent organizations. |
| doi_str_mv | 10.1016/j.ajo.2008.02.021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69135891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002939408001578</els_id><sourcerecordid>3556485891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-1f38b173884e8ff8ea7571f1c10aeaffa95b5119079f9c1485e9db7aea4e41963</originalsourceid><addsrcrecordid>eNp9kV9rHCEUxSW0JJu0HyAvZaDQt9l6d5xRKRTCNn8KKX1oSh_Fda6J01lN1Ank28dhFwJ5CFwQ8XcOnnMJOQW6BArd12Gph7BcUSqWdFUGDsgCBJc1CAnvyIJSuqplI9kROU5pKNeOM35IjkCwppWcL8jFOvgcwyPG5DBVzlf5DqubiDpv0ecq2Oof5ursFuuIo87YV7-0mUYdqx94ix6jzi74D-S91WPCj_vzhPy9OL9ZX9XXvy9_rs-ua9OILtdgG7EB3gjBUFgrUPOWgwUDVKO2Vst20wJIyqWVBphoUfYbXt4YMpBdc0K-7HzvY3iYMGW1dcngOGqPYUqqk9C0JXwBP78ChzBFX_6moGNMipKeFgp2lIkhpYhW3Ue31fFJAVVzxWpQpWI1V6zoqszs_GnvPG222L8o9p0W4NsOwFLEo8OoknHoDfYuosmqD-5N---v1GZ03hk9_scnTC8pVCoC9Wfe8bxiKiiFlovmGcHin74</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1644989770</pqid></control><display><type>article</type><title>Controversies in the Treatment of Wet Age-related Macular Degeneration</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Flores Moreno, Sandra ; Bautista Paloma, Javier</creator><creatorcontrib>Flores Moreno, Sandra ; Bautista Paloma, Javier</creatorcontrib><description>[...]Genentech has modified the molecule of bevacizumab without affecting the basis of its efficacy and now specifically addressed to treating this pathology. [...]ranibizumab was developed, it is forty times more expensive, although no indirect comparisons have proved significant differences between both treatments in efficacy.1-2 In this case, countries such as Italy, Germany, Austria, Finland, and New Zealand, is formally recommended to use bevacizumab instead of ranibizumab in AMD, while waiting for a head-to-head trial, which had to be promoted by independent organizations.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/j.ajo.2008.02.021</identifier><identifier>PMID: 18435977</identifier><identifier>CODEN: AJOPAA</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - adverse effects ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - etiology ; Clinical trials ; Fluorescein Angiography ; Humans ; Injections ; Macular degeneration ; Macular Degeneration - complications ; Macular Degeneration - drug therapy ; Ophthalmology ; Pharmaceutical industry ; Treatment Outcome ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity ; Vitreous Body</subject><ispartof>American journal of ophthalmology, 2008-05, Vol.145 (5), p.937-937</ispartof><rights>Elsevier Inc.</rights><rights>2008 Elsevier Inc.</rights><rights>Copyright Elsevier Limited May 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c386t-1f38b173884e8ff8ea7571f1c10aeaffa95b5119079f9c1485e9db7aea4e41963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002939408001578$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18435977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Flores Moreno, Sandra</creatorcontrib><creatorcontrib>Bautista Paloma, Javier</creatorcontrib><title>Controversies in the Treatment of Wet Age-related Macular Degeneration</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>[...]Genentech has modified the molecule of bevacizumab without affecting the basis of its efficacy and now specifically addressed to treating this pathology. [...]ranibizumab was developed, it is forty times more expensive, although no indirect comparisons have proved significant differences between both treatments in efficacy.1-2 In this case, countries such as Italy, Germany, Austria, Finland, and New Zealand, is formally recommended to use bevacizumab instead of ranibizumab in AMD, while waiting for a head-to-head trial, which had to be promoted by independent organizations.</description><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Bevacizumab</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - etiology</subject><subject>Clinical trials</subject><subject>Fluorescein Angiography</subject><subject>Humans</subject><subject>Injections</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - complications</subject><subject>Macular Degeneration - drug therapy</subject><subject>Ophthalmology</subject><subject>Pharmaceutical industry</subject><subject>Treatment Outcome</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Visual Acuity</subject><subject>Vitreous Body</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV9rHCEUxSW0JJu0HyAvZaDQt9l6d5xRKRTCNn8KKX1oSh_Fda6J01lN1Ank28dhFwJ5CFwQ8XcOnnMJOQW6BArd12Gph7BcUSqWdFUGDsgCBJc1CAnvyIJSuqplI9kROU5pKNeOM35IjkCwppWcL8jFOvgcwyPG5DBVzlf5DqubiDpv0ecq2Oof5ursFuuIo87YV7-0mUYdqx94ix6jzi74D-S91WPCj_vzhPy9OL9ZX9XXvy9_rs-ua9OILtdgG7EB3gjBUFgrUPOWgwUDVKO2Vst20wJIyqWVBphoUfYbXt4YMpBdc0K-7HzvY3iYMGW1dcngOGqPYUqqk9C0JXwBP78ChzBFX_6moGNMipKeFgp2lIkhpYhW3Ue31fFJAVVzxWpQpWI1V6zoqszs_GnvPG222L8o9p0W4NsOwFLEo8OoknHoDfYuosmqD-5N---v1GZ03hk9_scnTC8pVCoC9Wfe8bxiKiiFlovmGcHin74</recordid><startdate>20080501</startdate><enddate>20080501</enddate><creator>Flores Moreno, Sandra</creator><creator>Bautista Paloma, Javier</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20080501</creationdate><title>Controversies in the Treatment of Wet Age-related Macular Degeneration</title><author>Flores Moreno, Sandra ; Bautista Paloma, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-1f38b173884e8ff8ea7571f1c10aeaffa95b5119079f9c1485e9db7aea4e41963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Bevacizumab</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - etiology</topic><topic>Clinical trials</topic><topic>Fluorescein Angiography</topic><topic>Humans</topic><topic>Injections</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - complications</topic><topic>Macular Degeneration - drug therapy</topic><topic>Ophthalmology</topic><topic>Pharmaceutical industry</topic><topic>Treatment Outcome</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Visual Acuity</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Flores Moreno, Sandra</creatorcontrib><creatorcontrib>Bautista Paloma, Javier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Flores Moreno, Sandra</au><au>Bautista Paloma, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Controversies in the Treatment of Wet Age-related Macular Degeneration</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>2008-05-01</date><risdate>2008</risdate><volume>145</volume><issue>5</issue><spage>937</spage><epage>937</epage><pages>937-937</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><coden>AJOPAA</coden><abstract>[...]Genentech has modified the molecule of bevacizumab without affecting the basis of its efficacy and now specifically addressed to treating this pathology. [...]ranibizumab was developed, it is forty times more expensive, although no indirect comparisons have proved significant differences between both treatments in efficacy.1-2 In this case, countries such as Italy, Germany, Austria, Finland, and New Zealand, is formally recommended to use bevacizumab instead of ranibizumab in AMD, while waiting for a head-to-head trial, which had to be promoted by independent organizations.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18435977</pmid><doi>10.1016/j.ajo.2008.02.021</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9394 |
| ispartof | American journal of ophthalmology, 2008-05, Vol.145 (5), p.937-937 |
| issn | 0002-9394 1879-1891 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69135891 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Clinical trials Fluorescein Angiography Humans Injections Macular degeneration Macular Degeneration - complications Macular Degeneration - drug therapy Ophthalmology Pharmaceutical industry Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity Vitreous Body |
| title | Controversies in the Treatment of Wet Age-related Macular Degeneration |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T11%3A17%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Controversies%20in%20the%20Treatment%20of%20Wet%20Age-related%20Macular%20Degeneration&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Flores%20Moreno,%20Sandra&rft.date=2008-05-01&rft.volume=145&rft.issue=5&rft.spage=937&rft.epage=937&rft.pages=937-937&rft.issn=0002-9394&rft.eissn=1879-1891&rft.coden=AJOPAA&rft_id=info:doi/10.1016/j.ajo.2008.02.021&rft_dat=%3Cproquest_cross%3E3556485891%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1644989770&rft_id=info:pmid/18435977&rft_els_id=1_s2_0_S0002939408001578&rfr_iscdi=true |